Pro Vise Management Group, LLC Novartis Ag Transaction History

Pro Vise Management Group, LLC

  • $1.14 Billion
  • Q4 2024

A detailed history of Pro Vise Management Group, LLC transactions in Novartis Ag stock. As of the latest transaction made, Pro Vise Management Group, LLC holds 129,359 shares of NVS stock, worth $13.6 Million. This represents 1.1% of its overall portfolio holdings.

Number of Shares
129,359
Previous 131,890 1.92%
Holding current value
$13.6 Million
Previous $15.2 Million 17.02%
% of portfolio
1.1%
Previous 1.22%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025
SELL
$96.78 - $117.18 $244,950 - $296,582
-2,531 Reduced 1.92%
129,359 $12.6 Million
Q3 2024

Nov 12, 2024
BUY
$106.13 - $120.89 $354,155 - $403,409
3,337 Added 2.6%
131,890 $15.2 Million
Q2 2024

Aug 12, 2024
BUY
$92.57 - $107.37 $107,658 - $124,871
1,163 Added 0.91%
128,553 $13.7 Million
Q1 2024

May 09, 2024
BUY
$95.27 - $108.47 $292,859 - $333,436
3,074 Added 2.47%
127,390 $12.3 Million
Q4 2023

Feb 09, 2024
BUY
$92.27 - $101.54 $380,429 - $418,649
4,123 Added 3.43%
124,316 $12.6 Million
Q3 2023

Nov 08, 2023
BUY
$94.73 - $105.13 $345,859 - $383,829
3,651 Added 3.13%
120,193 $12.2 Million
Q2 2023

Aug 24, 2023
BUY
$92.52 - $104.91 $271,361 - $307,701
2,933 Added 2.58%
116,542 $11.8 Million
Q1 2023

May 05, 2023
BUY
$80.03 - $92.81 $45,377 - $52,623
567 Added 0.5%
113,609 $10.5 Million
Q4 2022

Feb 09, 2023
BUY
$75.55 - $92.52 $585,965 - $717,585
7,756 Added 7.37%
113,042 $10.3 Million
Q3 2022

Nov 09, 2022
BUY
$74.61 - $87.26 $625,007 - $730,977
8,377 Added 8.64%
105,286 $8 Million
Q2 2022

Aug 08, 2022
BUY
$80.52 - $93.75 $593,351 - $690,843
7,369 Added 8.23%
96,909 $8.19 Million
Q1 2022

Apr 27, 2022
BUY
$80.11 - $90.62 $135,626 - $153,419
1,693 Added 1.93%
89,540 $7.86 Million
Q4 2021

Jan 18, 2022
BUY
$79.7 - $88.13 $292,020 - $322,908
3,664 Added 4.35%
87,847 $7.68 Million
Q3 2021

Oct 20, 2021
BUY
$81.78 - $95.14 $310,927 - $361,722
3,802 Added 4.73%
84,183 $6.88 Million
Q2 2021

Aug 06, 2021
SELL
$85.24 - $94.15 $45,006 - $49,711
-528 Reduced 0.65%
80,381 $7.33 Million
Q1 2021

Apr 22, 2021
BUY
$83.5 - $98.47 $14,529 - $17,133
174 Added 0.22%
80,909 $6.92 Million
Q4 2020

Jan 19, 2021
BUY
$78.07 - $94.43 $90,170 - $109,066
1,155 Added 1.45%
80,735 $7.62 Million
Q3 2020

Oct 26, 2020
SELL
$82.14 - $91.0 $31,623 - $35,035
-385 Reduced 0.48%
79,580 $6.92 Million
Q2 2020

Aug 07, 2020
SELL
$80.93 - $91.1 $154,414 - $173,818
-1,908 Reduced 2.33%
79,965 $6.98 Million
Q1 2020

May 07, 2020
SELL
$70.67 - $99.01 $221,762 - $310,693
-3,138 Reduced 3.69%
81,873 $6.75 Million
Q4 2019

Feb 11, 2020
SELL
$84.35 - $95.37 $27,413 - $30,995
-325 Reduced 0.38%
85,011 $8.05 Million
Q3 2019

Nov 13, 2019
SELL
$85.54 - $94.26 $56,028 - $61,740
-655 Reduced 0.76%
85,336 $7.42 Million
Q2 2019

Aug 09, 2019
SELL
$75.4 - $92.8 $34,382 - $42,316
-456 Reduced 0.53%
85,991 $7.85 Million
Q1 2019

May 13, 2019
SELL
$75.32 - $86.15 $160,280 - $183,327
-2,128 Reduced 2.4%
86,447 $8.31 Million
Q4 2018

Feb 13, 2019
SELL
$73.66 - $82.02 $298,323 - $332,181
-4,050 Reduced 4.37%
88,575 $7.6 Million
Q3 2018

Nov 05, 2018
SELL
$66.94 - $77.43 $29,520 - $34,146
-441 Reduced 0.47%
92,625 $7.98 Million
Q2 2018

Aug 13, 2018
SELL
$64.91 - $73.36 $45,891 - $51,865
-707 Reduced 0.75%
93,066 $10.8 Million
Q1 2018

May 09, 2018
SELL
$70.39 - $84.15 $121,070 - $144,738
-1,720 Reduced 1.8%
93,773 $7.58 Million
Q4 2017

Feb 07, 2018
SELL
$72.33 - $77.64 $20,252 - $21,739
-280 Reduced 0.29%
95,493 $8.02 Million
Q3 2017

Nov 08, 2017
BUY
$74.14 - $77.27 $7.1 Million - $7.4 Million
95,773
95,773 $8.22 Million

Others Institutions Holding NVS

# of Institutions
1,468
Shares Held
134M
Call Options Held
1.4M
Put Options Held
1.61M
View Full List

About NOVARTIS AG

NVS Quotes by TradingView
  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $227B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Pro Vise Management Group, LLC Portfolio

Follow Pro Vise Management Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Vise Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Vise Management Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email